Announced details
Spinocerebellar degeneration
The Company has an administrative relationship with Kanagawa Prefecture under which it applied for the license to market regenerative medical products. The Company also holds an exclusive commercialization license agreement for Stemchymal® in Japan, but the licensor's name is not disclosed.
License to market regenerative medical products
Kanagawa Prefecture
Immaterial at this time. The Company will promptly disclose any matters requiring disclosure in the future.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stemchymal® |
| Counterparty | Kanagawa Prefecture |
| Relationship with the Company | The Company has an administrative relationship with Kanagawa Prefecture under which it applied for the license to market regenerative medical products. The Company also holds an exclusive commercialization license agreement for Stemchymal® in Japan, but the licensor's name is not disclosed. |
| Launch date | Not disclosed (sales and shipments are planned after the license and product approval are obtained) |
| Applicable area | Spinocerebellar degeneration |
| Award/certification name | License to market regenerative medical products |
| Awarding / certifying body | Kanagawa Prefecture |
| Impact on Business Performance | Immaterial at this time. The Company will promptly disclose any matters requiring disclosure in the future. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a structure enabling the Company to sell and ship Stemchymal® directly and promptly after obtaining product approval. The marketing license is legally required for domestic sales.